PET using 18F-FDG for treatment monitoring in patients with lymphoma is one of the most well-developed clinical applications. PET/CT is nowadays used during treatment to assess chemosensitivity, with response-adapted therapy given according to ‘interim’ PET in clinical practice to adults and children with Hodgkin lymphoma. PET is also used to assess remission from disease and to predict prognosis in the pretransplant setting. Mature data have been reported for the common subtypes of aggressive B-cell lymphomas, with more recent data also supporting the use of PET for response assessment in T-cell lymphomas. The Deauville five-point scale incorporating the Deauville criteria (DC) is recommended for response assessment in international guidelines. FDG uptake is graded in relation to the reference regions of normal mediastinum and liver. The DC have been validated in most lymphoma subtypes. The DC permit the threshold for adequate or inadequate response to be adapted according to the clinical context or research question. It is important for PET readers to understand how the DC have been applied in response-adapted trials for correct interpretation and discussion with the multidisciplinary team. Quantitative methods to perform PET in standardized ways have also been developed which may further improve response assessment including a quantitative extension to the DC (qPET). This may have advantages in providing a continuous scale to refine the threshold for adequate/inadequate response in specific clinical situations or treatment optimization in trials. qPET is also less observer-dependent and limits the problem of optical misinterpretation due to the influence of background activity.
Barrington SF, Carr R. Staging of Burkitt’s lymphoma and response to treatment monitored by PET scanning. Clin Oncol (R Coll Radiol). 1995;7:334–5. CrossRef
Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med. 1991;32:686–91. PubMed
Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52. CrossRefPubMed
Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32:1188–94. CrossRefPubMed
Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118:4053–61. CrossRefPubMedPubMedCentral
Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015;33:2523–9. CrossRefPubMed
Nols N, Mounier N, Bouazza S, Lhommel R, Costantini S, Vander Borght T, et al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:773–80. CrossRefPubMed
Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683–90.
Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115:272–8. CrossRefPubMed
Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19:414–9. CrossRefPubMed
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.
Society of Nuclear Medicine and Molecular Imaging. Clinical trials network. http://www.snmmi.org/Research/Content.aspx?ItemNumber=9937&navItemNumber=6832. Reston, VA: Society of Nuclear Medicine and Molecular Imaging. Accessed 6 April 2017.
Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol. 2012;30:4317–22. CrossRefPubMed
Ceriani L, Barrington S, Biggi A, Malkowski B, Metser U, Versari A, et al. Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. Hematol Oncol. 2016. doi: 10.1002/hon.2339. PubMed
Le Roux PY, Gastinne T, Le Gouill S, Nowak E, Bodet-Milin C, Querellou S, et al. Prognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging. 2011;38:1064–71. CrossRefPubMed
Kim SJ, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, et al. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol. 2015;2:e66–74. CrossRefPubMed
Radford J, Illidge T, Counsell N, Pettengell R, Johnson P, Wimperis J, et al. PET score following 3 cycles ABVD has greater prognostic significance than pre-treatment risk stratification in the RAPID trial in early stage Hodgkin lymphoma (HL) [Abstract 82]. Hematol Oncol. 2015;33(S1):100–80.
Johnson P, Federico M, Fossa A, O’Doherty M, Roberts T, Stevens L, et al. Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL study (CRUK/07/033) [Abstract 8]. Hematol Oncol. 2015;33(S1):100–80.
Gallamini A, Rossi A, Patti C, Picardi M, Di Raimondo F, Cantonetti M, et al. Interim PET adapted chemotherapy in advanced Hodgkin lymphoma. Results of the second interim analysis of the Italian GITIL/FIL DH0607 trial [Abstract 118]. Hematol Oncol 2015;33(S1):100–80.
Ceriani L, Martelli M, Gospodarowicz MK, Ricardi U, Ferreri AJ, Chiappella A, et al. Positron emission tomography/computed tomography assessment after Immunochemotherapy and irradiation using the Lugano Classification criteria in the IELSG-26 study of primary mediastinal B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2017;97:42–9. CrossRefPubMed
Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995;36:252–8. PubMed
Römer W, Hanuaske AR, ZieglerS, Thödtmann R, Weber W, Fuchs C, Enne W, Herz M, Nerl C, Garbrecht M, Schwaiger M. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91(12): 4464–71
Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983–95. PubMed
Wang X, Fan Y, Zhang Y, Yang Z, Zhou N, Liu C, et al. Evaluating early interim F-18-FDG PET/CT with Peking criteria for predicting the outcome in diffuse large B-cell lymphoma. Report of the 6th International Workshop in Lymphoma [Abstract A5]. Leuk Lymphoma. 2017. doi: 10.1080/10428194.2017.1298752.
Johnson PW. Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? Hematology Am Soc Hematol Educ Program. 2016;2016:316–22. PubMed
Landman-Parker J, Wallace H, Hasenclever D, Balwierz W, Karlen J, Fossa A, et al. First international intergroup study for classical Hodgkin lymphoma in children and adolescents: EuroNet-PHL-C1. Report of the latest interim analysis [Abstract 35]. Haematologica. 2016;101(s5):1–80.
Kelly K, Cole P, Chen L, Roberts K, Hodgson D, McCarten K, et al. Phase III study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin lymphoma (stages IIIB/IVB) (AHOD0831): a report from the Children’s Oncology Group. Blood. 2015;126:3927. CrossRef
Zijlstra JM, Burggraaff CN, Kersten MJ, Barrington SF, EHA Scientific Working Group on Lymphoma. FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice? Haematologica. 2016;101:1279–83. CrossRefPubMedPubMedCentral
Hertzberg M, Gandhi M, Butcher B, Columbus R, Taper J, Trotman J, et al. Early treatment intensification with R-ICE chemotherapy followed by autologous stem cell transplantation (ASCT) using Zevalin-BEAM for patients with poor risk diffuse large B-cell lymphoma (DLBCL) as identified by interim PET/CT scan performed after four cycles of R-CHOP-14: a multicenter phase II study of the Australasian Leukaemia Lymphoma Study Group (ALLG). Blood, 2015;126:815.
Duehrsen U, Huettmann A, Mueller S, Hertenstein B, Kotzerke J, Mesters R, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas – a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial). Blood. 2014;124:391.
Duehrsen U, Müller SP, Rekowski J, Hertenstein B, Franzius C, Mesters R, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas – interim PET-based outcome prediction and treatment changes in patients with B cell lymphomas participating in the PETAL trial. Blood 2016;128:1857.
Sehn LH, Hardy EL, Gill KK, Al-Tourah AJ, Shustik J, Macpherson NA, et al. Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood. 2014;124:392.
- FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Sally F. Barrington
- Springer Berlin Heidelberg
European Journal of Nuclear Medicine and Molecular Imaging
Ausgabe Sonderheft 1/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089